328 related articles for article (PubMed ID: 21909266)
21. Dementia and neurocognitive disorders due to HIV-1 infection.
Ances BM; Ellis RJ
Semin Neurol; 2007 Feb; 27(1):86-92. PubMed ID: 17226745
[TBL] [Abstract][Full Text] [Related]
22. Current understanding of HIV-associated neurocognitive disorders pathogenesis.
Gannon P; Khan MZ; Kolson DL
Curr Opin Neurol; 2011 Jun; 24(3):275-83. PubMed ID: 21467932
[TBL] [Abstract][Full Text] [Related]
23. Insights into the Gene Expression Profiles of Active and Restricted Red/Green-HIV
Edara VV; Ghorpade A; Borgmann K
J Virol; 2020 Feb; 94(6):. PubMed ID: 31896591
[TBL] [Abstract][Full Text] [Related]
24. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort.
Robertson KR; Su Z; Margolis DM; Krambrink A; Havlir DV; Evans S; Skiest DJ;
Neurology; 2010 Apr; 74(16):1260-6. PubMed ID: 20237308
[TBL] [Abstract][Full Text] [Related]
25. Brain PET Imaging: Value for Understanding the Pathophysiology of HIV-associated Neurocognitive Disorder (HAND).
Sinharay S; Hammoud DA
Curr HIV/AIDS Rep; 2019 Feb; 16(1):66-75. PubMed ID: 30778853
[TBL] [Abstract][Full Text] [Related]
26. Associations of antiretroviral therapy and comorbidities with neurocognitive outcomes in HIV-1-infected patients.
Siangphoe U; Archer KJ; Nguyen C; Lee KR
AIDS; 2020 May; 34(6):893-902. PubMed ID: 32028325
[TBL] [Abstract][Full Text] [Related]
27. HIV-associated neurocognitive disorders: antiretroviral regimen, central nervous system penetration effectiveness, and cognitive outcomes.
Cross HM; Combrinck MI; Joska JA
S Afr Med J; 2013 Sep; 103(10):758-62. PubMed ID: 24079630
[TBL] [Abstract][Full Text] [Related]
28. Antiretroviral therapy down-regulates innate antiviral response genes in patients with AIDS in sub-saharan Africa.
Boulware DR; Meya DB; Bergemann TL; Williams D; Vlasova-St Louis IA; Rhein J; Staddon J; Kambugu A; Janoff EN; Bohjanen PR
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):428-38. PubMed ID: 20838227
[TBL] [Abstract][Full Text] [Related]
29. Peripheral immune dysregulation in the ART era of HIV-associated neurocognitive impairments: A systematic review.
Williams ME; Ipser JC; Stein DJ; Joska JA; Naudé PJW
Psychoneuroendocrinology; 2020 Aug; 118():104689. PubMed ID: 32479968
[TBL] [Abstract][Full Text] [Related]
30. A peripheral monocyte interferon phenotype in HIV infection correlates with a decrease in magnetic resonance spectroscopy metabolite concentrations.
Pulliam L; Rempel H; Sun B; Abadjian L; Calosing C; Meyerhoff DJ
AIDS; 2011 Sep; 25(14):1721-6. PubMed ID: 21750421
[TBL] [Abstract][Full Text] [Related]
31. Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer's disease?
Fulop T; Witkowski JM; Larbi A; Khalil A; Herbein G; Frost EH
J Neurovirol; 2019 Oct; 25(5):634-647. PubMed ID: 30868421
[TBL] [Abstract][Full Text] [Related]
32. HIV-associated neurological disorders: a guide to pharmacotherapy.
Tan IL; McArthur JC
CNS Drugs; 2012 Feb; 26(2):123-34. PubMed ID: 22201342
[TBL] [Abstract][Full Text] [Related]
33. Molecular Signatures of HIV-1 Envelope Associated with HIV-Associated Neurocognitive Disorders.
Evering TH
Curr HIV/AIDS Rep; 2018 Feb; 15(1):72-83. PubMed ID: 29460224
[TBL] [Abstract][Full Text] [Related]
34. Prefrontal dopaminergic and enkephalinergic synaptic accommodation in HIV-associated neurocognitive disorders and encephalitis.
Gelman BB; Lisinicchia JG; Chen T; Johnson KM; Jennings K; Freeman DH; Soukup VM
J Neuroimmune Pharmacol; 2012 Sep; 7(3):686-700. PubMed ID: 22391864
[TBL] [Abstract][Full Text] [Related]
35. Genome-wide association study of HIV-associated neurocognitive disorder (HAND): A CHARTER group study.
Jia P; Zhao Z; Hulgan T; Bush WS; Samuels DC; Bloss CS; Heaton RK; Ellis RJ; Schork N; Marra CM; Collier AC; Clifford DB; Gelman BB; Sacktor N; Morgello S; Simpson DM; McCutchan JA; Barnholtz-Sloan JS; Franklin DR; Rosario D; Letendre SL; Grant I; Kallianpur AR;
Am J Med Genet B Neuropsychiatr Genet; 2017 Jun; 174(4):413-426. PubMed ID: 28447399
[TBL] [Abstract][Full Text] [Related]
36. HIV-1 neuroimmunity in the era of antiretroviral therapy.
Kraft-Terry SD; Stothert AR; Buch S; Gendelman HE
Neurobiol Dis; 2010 Mar; 37(3):542-8. PubMed ID: 20044002
[TBL] [Abstract][Full Text] [Related]
37. Loss of cerebellar neurons in the progression of lentiviral disease: effects of CNS-permeant antiretroviral therapy.
Wächter C; Eiden LE; Naumann N; Depboylu C; Weihe E
J Neuroinflammation; 2016 Oct; 13(1):272. PubMed ID: 27737697
[TBL] [Abstract][Full Text] [Related]
38. Induction of Heme Oxygenase-1 Deficiency and Associated Glutamate-Mediated Neurotoxicity Is a Highly Conserved HIV Phenotype of Chronic Macrophage Infection That Is Resistant to Antiretroviral Therapy.
Gill AJ; Kovacsics CE; Vance PJ; Collman RG; Kolson DL
J Virol; 2015 Oct; 89(20):10656-67. PubMed ID: 26269184
[TBL] [Abstract][Full Text] [Related]
39. Alterations in Brain Cannabinoid Receptor Levels Are Associated with HIV-Associated Neurocognitive Disorders in the ART Era: Implications for Therapeutic Strategies Targeting the Endocannabinoid System.
Swinton MK; Sundermann EE; Pedersen L; Nguyen JD; Grelotti DJ; Taffe MA; Iudicello JE; Fields JA
Viruses; 2021 Aug; 13(9):. PubMed ID: 34578323
[TBL] [Abstract][Full Text] [Related]
40. White matter micro-structural changes in ART-naive and ART-treated children and adolescents infected with HIV in South Africa.
Hoare J; Fouche JP; Phillips N; Joska JA; Paul R; Donald KA; Thomas KG; Stein DJ
AIDS; 2015 Sep; 29(14):1793-801. PubMed ID: 26372385
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
